1,091 Shares in ICON Public Limited (NASDAQ:ICLR) Purchased by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC bought a new position in shares of ICON Public Limited (NASDAQ:ICLR) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,091 shares of the medical research company’s stock, valued at approximately $229,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. FDx Advisors Inc. grew its position in ICON Public by 13.6% during the fourth quarter. FDx Advisors Inc. now owns 3,527 shares of the medical research company’s stock worth $740,000 after buying an additional 422 shares during the period. Kornitzer Capital Management Inc. KS grew its position in ICON Public by 40.6% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock worth $20,363,000 after buying an additional 28,050 shares during the period. Sierra Ocean LLC acquired a new position in ICON Public during the fourth quarter worth about $29,000. Entropy Technologies LP grew its position in ICON Public by 472.2% during the fourth quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock worth $1,295,000 after buying an additional 5,095 shares during the period. Finally, Tributary Capital Management LLC grew its position in ICON Public by 116.1% during the fourth quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock worth $828,000 after buying an additional 2,122 shares during the period. 95.61% of the stock is currently owned by institutional investors and hedge funds.

ICON Public Stock Performance

Shares of ICLR opened at $201.39 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. The company has a market capitalization of $16.61 billion, a price-to-earnings ratio of 21.13, a PEG ratio of 1.86 and a beta of 1.19. The company’s 50 day simple moving average is $202.90 and its 200 day simple moving average is $244.47. ICON Public Limited has a 1 year low of $181.51 and a 1 year high of $347.72.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.01. The business had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. On average, sell-side analysts predict that ICON Public Limited will post 13.38 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ICLR. JPMorgan Chase & Co. lowered their target price on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Barclays lowered their price target on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a research report on Friday. Leerink Partners reiterated an “outperform” rating and issued a $255.00 price target (down from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Truist Financial lowered their price target on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Robert W. Baird lowered their price target on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 20th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $281.00.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.